When Manual Testing No Longer Scales: What High-Volume Brands Should Know About Lab Automation

There’s a specific inflection point most growing supplement brands hit — and their contract lab usually sees it before they do. Orders are up, SKU count has doubled, and the 10-business-day turnaround that worked fine last year is now holding up a product launch. The instinct is to shop around for a faster lab. The better question is whether the lab you’re already using has the automation infrastructure that makes speed structurally possible — not just a commitment made during the onboarding call.

The US dietary supplement market surpassed $60 billion in annual sales in 2023, and the trajectory hasn’t changed. That volume pressure has landed squarely on contract testing labs, many of which built their workflows around manual processes that functioned fine at lower throughput. The labs investing in automation right now aren’t chasing a trend. They’re responding to the math.

What “Lab Automation” Actually Means in a Testing Context

Laboratory automation in analytical chemistry isn’t a single thing — it means different operations depending on the method and the workflow. In supplement, cosmetic, and food testing, there are four distinct layers worth understanding before you evaluate a testing partner on this basis.

Sample preparation automation. This is where the largest efficiency gains actually live. Automated liquid handlers — platforms from Hamilton, Tecan, and similar manufacturers — perform dilutions, extractions, and plate preparation with pipetting coefficients of variation (CV) below 0.5%. Experienced manual operators typically run 2–5% CV on those same operations. For potency testing or any method where linearity and analyte recovery matter, that difference shows up directly in your results.

Instrument automation. Modern HPLC and ICP-MS systems can queue and run overnight sequences unattended, with autosamplers that hold 100 or more vials. A potency panel that takes an analyst eight hours to set up and monitor manually can be configured in 45 minutes and produce results by morning. The instrument performs the same analytical work — automation removes the time constraint and the fatigue variable.

Microbiology automation. Automated colony counters, growth-based detection systems, and pathogen identification platforms like MALDI-TOF have compressed turnaround times considerably. Pathogen identification that traditionally required 48–72 hours of culture-based work can now be completed in under 8 hours with certain systems — without sacrificing the method defensibility that USP <61> and <62> compliance demands.

Data and LIMS integration. Laboratory Information Management Systems that pull raw instrument output directly into structured records eliminate transcription errors and accelerate final report generation. For clients who need COAs quickly — especially Amazon sellers responding to a listing review — this backend layer matters more than most brands realize. The difference between a well-integrated LIMS and a spreadsheet-based data entry workflow shows up in COA formatting consistency, method traceability, and audit readiness.

The ISO 17025 Validation Requirement That Changes the Equation

Here’s something that often gets glossed over in lab automation discussions: under ISO 17025:2017, any modification to a validated analytical procedure — including automating a step that was previously performed manually — triggers a revalidation requirement.

Section 7.2.2 of the standard is explicit. If a lab implements a robotic liquid handler to replace manual extraction, it must demonstrate that the modified method still meets the same accuracy, precision, linearity, and recovery criteria as the original. No assumed equivalence. Documented evidence only.

This is actually a feature of accredited lab operations, not a limitation. When a properly accredited lab tells you they run an automated workflow, you can reasonably expect that workflow has been formally verified and reviewed by an accreditation body — A2LA, Perry Johnson Laboratories, or NVLAP in the US context. Those assessors examine method validation records during every assessment cycle.

The risk exists on the other side. Labs that adopt automation without proper revalidation create hidden compliance exposure for their clients. If your product ends up under FDA scrutiny or Amazon compliance review, your testing documentation needs to hold. COAs referencing automated workflows from a lab that skipped revalidation are a liability that often doesn’t surface until the worst possible moment.

When we bring a new automated workflow online here, the revalidation package — recovery studies, precision data, method comparison against the original procedure — gets completed before a single client sample runs on that system. That’s not regulatory overcaution; it’s what sound quality management looks like.

Where Automation Delivers Real ROI — and Where It Doesn’t

Not every test benefits equally from automation. From the lab’s perspective, here’s a realistic breakdown.

High return:

• Heavy metals panels by ICP-MS (arsenic, cadmium, lead, mercury — the analytes most relevant to Prop 65 and FDA compliance). These require consistent sample digestion and dilution, exactly the operations where robotic liquid handlers perform best. Throughput can increase 3–4× for the same headcount.
• Microbiological plate counts under USP <61>. Automated colony counters eliminate the subjectivity inherent in manual counting and can process a full batch of plates in under 10 minutes.
• Multi-analyte potency panels by HPLC-UV or HPLC-MS/MS. Overnight autosampler queues mean 60–80 samples can process while the lab is closed.

Marginal return:

• Single-analyte tests on batches of five or fewer samples. The instrument setup and system suitability overhead for automated liquid handlers doesn’t yield meaningful efficiency at that scale.
• Methods requiring analyst judgment — visual identifications, organoleptic evaluation, structural confirmation where spectral interpretation matters. There’s no automation path for that expertise.

The honest ROI number for a contract lab running 500+ samples per month in heavy metals and potency testing: automation typically cuts cost-per-sample by 25–40% while reducing turnaround from 10–12 business days to 5–7. That’s the realistic operational range. Vendor claims of 80% cost reduction exist mostly in controlled proof-of-concept settings, not in production environments handling variable product matrices and full regulatory compliance documentation.

What Brands Should Actually Be Asking Their Contract Lab

You don’t need to inventory your testing partner’s instrument room to make a sound decision. But a few specific questions reveal more than any capabilities brochure.

“What percentage of your sample prep for heavy metals is automated?” A real number with a real answer is a good sign. “We use automation where possible” without specifics usually signals the investment hasn’t been made at meaningful scale.

“Can you share the method validation summary for your ICP-MS heavy metals procedure?” An ISO 17025 accredited lab should be able to provide this. Not the full validation report, but at minimum a method scope document with documented performance criteria — LOD, LOQ, recovery range, and precision data across representative matrices.

“What is your actual 90th-percentile turnaround time over the last 90 days?” Not the stated target. Actual performance, from sample receipt to final COA issuance, including the occasional outlier batch. A lab confident in its processes answers this without hesitation.

“If a result comes back out of specification, what is your OOS investigation process?” A lab with a defined out-of-specification investigation procedure — one that involves retesting, root cause documentation, and a determination of whether the deviation was analytical or a true product failure — operates differently from a lab that simply reruns the sample and reports the better number. That difference matters considerably when you’re defending a batch to a retailer, an auditor, or a regulator.

If your lab can’t answer these questions fluently, that’s information too.

The Bigger Picture for Growing Brands

The supplement and cosmetic brands hitting real growth — the ones moving from $2M to $15M in revenue, expanding from DTC to retail alongside Amazon — consistently underestimate how much their testing program needs to scale with them. A lab that worked well at 10 SKUs and a handful of product launches per year may not be the right partner at 50 SKUs and a quarterly launch cadence.

Automation infrastructure is one of the cleaner signals of whether a lab is genuinely built for that volume. It’s not the only signal. Documentation culture, method breadth, accreditation scope, and communication during turnaround crunches all matter. But a lab that has made real capital investment in automated sample prep, instrument queuing, and LIMS integration has implicitly committed to a production model that assumes consistent high volume. That structural alignment — or the absence of it — matters more than it usually gets credit for in vendor selection conversations.

A lab promising 3-day turnaround on a full heavy metals panel with a staff of four analysts is either understating their workload or their accuracy. Ask the question anyway. The answer tells you everything.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Software Validation and 21 CFR Part 11 Compliance for Lab Systems — Aurora TIC provides regulatory consulting for LIMS validation, GAMP5 frameworks, and FDA audit readiness for regulated labs and manufacturers.
• Raw Material Release Testing and COA Verification for Global Buyers — Ayah Labs supports ingredient manufacturers and distributors with contract testing, supplier qualification, and multi-compendial COA review.